Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Koselugois a small molecule inhibitory drug targeting the MEK signaling pathway, and its core efficacy is reflected in its specific effect on specific neurofibromas, by blocking th···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：258
Koselugo, as a small molecule blocker of the MEK signaling pathway, has a core effect on specific neurofibromatosis by inhibiting the growth and proliferation mechanism of tumor ce···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：313
Koselugo is a small molecule inhibitor targeting the MEK signaling pathway, mainly used to treat specific types of neurofibromatosis, by blocking the growth and proliferation of tu···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：286
Koselugo is a small molecule inhibitor targeting MEK, which plays the role of a blocker on the mitogen activation link, and its core efficacy is reflected in the inhibition of MEK ···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：261
Koselugo is a small molecule MEK inhibitor and a repressor of mitogen activation, and its core role is to inhibit the activation of MEK signaling pathways, thereby effectively inte···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：283
Koselugois a small molecule MEK inhibitor (mitogen activation inhibitor), and its main mechanism of action is to block the growth and proliferation of tumor cells by inhibiting the···【more】
Article source：Captain MedicineRelease date：2024-08-21Recommended：227
The therapeutic effect of Mitotane is aimed at adrenal cortical carcinoma, hyperplasia, and tumor-induced cortisolism without surgical options, and is characterized by fine regulat···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：282
Anamorelin is the first drug specifically for the treatment of cachexia launched in Japan in 2021, which stimulates appetite by mimicking ghrelin; As a ghrelin receptor agonist, it···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：203
In 2021, Japan launched Anamorelin, the world's first drug specifically for the treatment of cachexia. By mimicking the effects of ghrelin, the patient's appetite and body ···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：302
Anamorelin is the world's first drug specifically for the treatment of cachexia, which increases appetite and improves body weight and muscle mass by activating ghrelin recepto···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：274
In 2021, Ono Pharmaceutical of Japan launched Anamorelin, a ghrelin receptor agonist that can effectively increase patients' appetite and weight. This drug significantly improv···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：362
Anamorelin is the first cachexia treatment drug launched in Japan in 2021, which is able to stimulate appetite and increase weight by mimicking ghrelin. This ghrelin receptor agoni···【more】
Article source：Captain MedicineRelease date：2024-08-20Recommended：301
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：2272025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：4542024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：2342025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：2472025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：2272025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：2572025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：2362025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended：2182025-27-11
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
